Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia.

Item

http://www.wikidata.org/entity/Q38269589

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia.

@en

type

Item

label

Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia.

@en

prefLabel

Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia.

@en

P1476

Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia

@en

P2093

Gianluca Tomasello

http://www.w3.org/2001/XMLSchema#string

P2860

Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?

Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis

Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

P304

15-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17512433.2015.984688

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Margherita Ratti

P577

2014-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268529334

http://www.w3.org/2001/XMLSchema#string

P698

25409861

http://www.w3.org/2001/XMLSchema#string